Overview

Efficacy and Safety of Romiplostim Versus Eltrombopag in the Treatment of Thrombocytopenia in Patients With Wiskott-Aldrich Syndrome

Status:
Recruiting

Trial end date:
2023-07-30

Target enrollment:

Participant gender:

Summary

This is a prospective, open-label, randomized, two-arm clinical trial conducted to evaluate the safety and efficacy of romiplostim in comparison with eltrombopag in the treatment of thrombocytopenia in patients with Wiskott-Aldrich syndrome

Phase:

Phase 2

Details

Lead Sponsor:

Federal Research Institute of Pediatric Hematology, Oncology and Immunology